Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Inclusion Criteria: * Histologically or cytologically confirmed non-keratinizing differentiated (World Health Organization WHO Type II) or undifferentiated (WHO Type III) nasopharyngeal carcinoma (NPC) that has recurred at regional or / and distant sites * Measurable disease according to the RECIST criteria (version 1.1) for the evaluation of measurable disease * Received one or more lines of chemotherapy, which must include prior treatment with a platinum agent either for the treatment of metastatic or recurrent disease * Experienced progression of disease within 6 months following completion of a platinum-based combination therapy as part of (neo)-adjuvant therapy * Male or female subjects with age: 18-79 years old * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * No prior immunotherapy * Written informed consent obtained for clinical trial participation and providing archival tumor tissue, if available * Females of childbearing potential or non-sterilized male who are sexually active must use a highly effective method of contraception * Females of childbearing potential must have negative serum or urine pregnancy test * Have life expectancy ≥ 3 months * Adequate organ function as defined as: Absolute neutrophil count ≥ 1.5 x 10\^9/L, Platelet count ≥ 100 x 10\^9/L, Hemoglobin \>= 8.0 g/dL, Serum alanine aminotransferase (\[ALT\]; serum glutamate-pyruvate transferase \[SGPT\]), or serum aspartate aminotransferase \[AST\] where available at the c…